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tissue from surgical resection was tested for MAGE-A3 expres-
sion, by quantitative reverse-transcription polymerase chain
reaction (RT-PCR).
Findings: The overall rate of MAGE-A3 expression was 41% (37%
in Taiwan and 48% in Thailand, from 132 valid samples). MAGE-
A3 expression was lower in patients with HBV infection (33.3%)
than in HCV-infected patients (63.0%). No difference in MAGE-
A3 expression was noted for the following factors: age, gender,
liver cirrhosis, Child-Pugh class, chronic alcohol abuse, number
and size of (largest) tumours. No clinical effects on survival were
associated with MAGE-A3 expression in this HCC Asian popula-
tion. The hazard ratio (HR) for the disease-free interval for
MAGE-A3-positive versus MAGE-A3-negative patients was 1.06
(p = 0.82; HR adjusted for T stage, tumour number and size, cir-
rhosis, Child-Pugh score, and ECOG performance status was
1.40 [p = 0.29]). HRs for disease-free and overall survival were
1.03 (p = 0.91) and 0.97 (p = 0.94), respectively; adjusted HRs were
1.32 (p = 0.37) and 1.33 (p = 0.63). However, because of the small
number of patients, no subset analysis by stage or other variables
that affect disease-free and overall survival could be done.
Interpretation: MAGE-A3 can be assessed byRT-PCR on surgically
resected HCC. The overall expression rate is sufficient to consider
MAGE-A3 a target for active immunotherapy. The relatively higher
expression in HCV-infected patients has no explanation, so far.
Clinical evaluation of MAGE-A3 antigen-specific cancer immuno-
therapeutics in early HCC after resection is being discussed.
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Background: This study investigated the role of additional high
dose rate (HDR) brachytherapy boost, in patients with malignant
glioma who have residual lesions after conventional external-
beam radiotherapy (EBRT).
Methods: Thirty patients were included in this prospective,
non-randomised trial. After initial surgical intervention and EBRT
given as 60 Gy/30 fractions/6 weeks, patients with a post-radia-
tion residual lesion not more than 6 cm in maximum dimension
were selected: 16 patients in the experimental group and 14 in the
control group. Patients in the experimental group received a
brachytherapy boost dose of 24–25 Gy/5–6 fractions daily, using
a high dose rate Ir192 source.
Findings: Median follow-up was 1 year (range 0.4–7.5 years).
Median overall survival (OS) was 14 months for the boost group
and 11 months for the control group (p = 0.49). Median progres-
sion-free survival (PFS) was 10 months for the boost group and
8 months for control (p = 0.44). Acute and late toxicities were
low. Two patients developed limited CSF leakage, and one patient
reported severe pain.
Interpretation: Increasing the dose of radiation by additional
HDR brachytherapy boost prolonged the median OS by 3
months and PFS by 2 months, but the number of patients
was too small to reach statistical significance. The implant
was tolerable and the toxic effects of an additional HDR brach-
ytherapy boost were low, so this may be considered a safe
treatment option.
Funding: None.
The authors declared no conflicts of interest.
doi:10.1016/j.ejcsup.2011.02.028
P28 CHILDHOOD CANCER AND ITS IMPACT ON THE FAMILY—AN
ASIAN EXPERIENCE
L. Aung a,*, M.Y. Chan a, S.M. Sabai b, T.D. Khaing b, H.M.
Verkooijen c. a Paediatric Medicine and Subspecialties, KK Womens
and Childrens Hospital, Singapore. b Division of Pediatric Hematology-
Oncology, National University Hospital, Singapore. c National
University of Singapore, Singapore
Background: In Singapore, there is a lack of information on the
impact of childhood cancer on the family as a whole. We set out
to assess medical and non-medical costs of childhood cancer and
its psychosocial impact.
Methods: All patients diagnosed and treated at the Department
of Pediatrics, KK Womens and Childrens Hospital and National
University Hospital, Singapore, were eligible. Families were given
two self-administered questionnaires: one about the child and
family, and an impact-on-family scale. The total score was
obtained by summation of all scores, with a high score correlating
to high impact.
Findings: 79 parents were enrolled during the study period
(October, 2008–February, 2009). 48 of the children (61%) were
male. 57 (72%) of respondents were mothers and 51% had chil-
dren younger than 5 years. Most respondents were Chinese
(54%), followed by foreign (not from Singapore) patients at
33%. 44 (56%) had children with haematological malignancies,
and 38% had children with solid tumours. Reported financial
burden was higher than in US and Italian studies. No Malaysian
or Indian care-givers reported a high familial or social burden
(p = 0.05). All Malaysian and Indian care-givers reported low-to-
moderate psychological burden, whereas a large proportion of
Chinese reported a high burden (p = 0.03). Chinese reported the
highest levels of mastering (ie, coping strategies) within ethnic
subgroups (p = 0.001). Cronbachs alpha internal reliability was
0.64.
Interpretation: Overall, the burden of childhood cancer in Sin-
gapore is comparable to other countries. Factors associated
with high impact are ethnicity, employment status, and leave
status. Use of the impact-on-family scale needs further
research to see whether all domains are applicable to our local
culture.
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